AstraZeneca, Daiichi Sankyo unveil Phase 3 results for TROP2-directed ADC
The first Phase 3 results for AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody drug conjugate showed a statistically significant…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
04 Jul 23
The first Phase 3 results for AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody drug conjugate showed a statistically significant…
04 Jul 23
Through its B2C division, i-Health, dsm-firmenich plans to increase access to Lactéol, which is the over-the-counter postbiotic supplement…
04 Jul 23
United Malt is a commercial maltster that makes bulk malt for brewers, craft brewers, distillers, and food companies…
04 Jul 23
The list price for HULIO is 5% less than the current list price of the rheumatoid arthritis drug…
04 Jul 23
The filing follows the recommendation from regulators and global public health bodies to develop monovalent XBB.1.5 COVID-19 vaccines
04 Jul 23
Launches authorized generic for Xyrem (sodium oxybate) in the US, representing another new complex generic product launch
03 Jul 23
Hyrimoz HCF is approved in the US to treat indications including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis,…
03 Jul 23
The consideration includes $1.75bn in upfront cash and up to $750m in the form of potential milestone payments…
03 Jul 23
The approval in China was based on the results from the global Phase 3 ADAPT trial in which…
03 Jul 23
Both firms decided to voluntarily withdraw the US RET-mutant MTC indication following consultation with the FDA, as the…